Study S001339

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT04199728
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 27
Start: 2021-10-18
Primary completion: 2023-09-13
Lead sponsor: Milton S. Hershey Medical Center
Conditions: Opiate Substitution Treatment; Opioid-Related Disorders
Interventions: DRUG:Liraglutide Pen Injector; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: NIH:1UG3DA050325-01

Registered primary outcomes

Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS) [Baseline (Day 1), End of the target drug dose (Day 19)]
Change in Ambient Drug Craving Over Time as Measured by Visual Analog Scale (VAS) [Baseline (Day 1), Treatment Days (Days 2-19)]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0048895	Bridging Preclinical Promise and Clinical Uncertainty: The Role of GLP-1 Receptor Agonists in Opioid Use Disorder — A Scoping Review Protocol Charles Amoatey Odonkor, Open Science Framework	2026	Protocol	DOI	cites ClinicalTrials.gov:NCT04199728
R0004376	Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder. Freet CS, Addiction science & clinical practice	2024	Protocol	PMID 39061093 DOI	cites ClinicalTrials.gov:NCT04199728; registry reference DERIVED:39061093